Advantages of Working with NMCCA
NMCCA has several features that will appeal to study sponsors of oncology trials.
- Clinical trial sponsors will find we are a single entry point for contracting and managing oncology trials at multiple sites in New Mexico.
- NMCCA utilizes several centralized IRBs for all participating sites. Most pharmaceutical-sponsored trials are sent to the Western IRB. NCI-funded trials are sent to the University of New Mexico’s IRB; some of the NCI trials also are reviewed by the NCI’s Central IRB.
- Staff at one central site performs all administrative procedures, such as regulatory management, contracting, budgeting and auditing.
- A single contact person is available to answer questions and coordinate paperwork regardless of the number of NMCCA sites taking part in the trial.
- Our participant list includes specialists in all areas of oncology.
- NMCCA has both cooperative and pharmaceutical company-sponsored clinical trials open for enrollment at multiple sites. Our primary focus is therapeutic Phase I, II and III trials; however, we do participate in cancer clinical trials on prevention, screening and quality of life.
- The time spent to accrue patients to a single trial decreases when the study is opened at multiple sites.
- NMCCA represents patients from multiple healthcare systems and all major insurance payers in our area.
- New Mexico contains a wide range of ethnic populations available to take part in studies.
2010 Census Report
| White persons, percent | 68.4% |
| Black persons, percent | 2.1% |
| American Indian and Alaska Native persons, percent | 9.4% |
| Asian persons, percent | 1.4% |
| Native Hawaiian and Other Pacific Islander, percent | 0.1% |
| Persons reporting two or more races, percent | 3.7% |
| Persons of Hispanic or Latino origin, percent | 46.3% |
| White persons not Hispanic, persons | 40.5% |
English
Spanish
